PD Dr. Dr. Imke Atreya

Medizinische Fakultät

Anti-beta 7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing (2023) Sommer K, Heidbreder K, Kreiß L, Dedden M, Paap EM, Wiendl M, Becker E, et al. Journal article, Original article Nr4a1-dependent non-classical monocytes are important for macrophage-mediated wound healing in the large intestine (2023) Heidbreder K, Sommer K, Wiendl M, Müller T, Atreya I, Hildner K, Neurath M, Zundler S Journal article IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells. (2023) Ullrich K, Derdau J, Baltes C, Battistella A, Rosso G, Uderhardt S, Schulze L, et al. Journal article Increased Motility and Suppression of Ex Vivo–Expanded Regulatory T Cells Designed for Adoptive Transfer Therapy in Ulcerative Colitis (2023) Müller T, Liu L, Czerwinski T, Wiesinger M, Dedden M, Paap EM, Ullrich K, et al. Journal article How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes (2022) Atreya I, Neurath M Journal article, Review article Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells (2022) Schweda A, Becker E, Wiendl M, Atreya R, Atreya I, Müller T, Neurath M, Zundler S Journal article Vedolizumab blocks alpha 4 beta 7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis (2022) Besendorf L, Müller T, Geppert CI, Schneider I, Mühl L, Atreya I, Vitali F, et al. Journal article Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets (2022) Becker E, Schweda A, Ullrich K, Voskens C, Atreya R, Müller T, Atreya I, et al. Journal article Epithelial RAC1-dependent cytoskeleton dynamics controls cell mechanics, cell shedding and barrier integrity in intestinal inflammation (2022) Martínez Sánchez LdC, Phuong Anh Ngo , Pradhan R, Becker LS, Böhringer D, Soteriou D, Kubankova M, et al. Journal article Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease (2022) Schneider I, Allner C, Mühl L, Melde M, Lissner D, Mantzivi E, Glauben R, et al. Journal article